| Title | Venue | Year | Impact | Source |
| 301 | Rapid impact of COVID-19 infection on semen quality: a case report N/A | Transl Androl Urol | 2022 | | LitCov and CORD-19 |
| 302 | Cerebral White Matter Injury in a Newborn Infant With COVID-19: A Case Report N/A | Neurol Clin Pract | 2022 | | LitCov |
| 303 | Twin crises in Nepal: covid-19 and climate change N/A | BMJ | 2022 | | LitCov |
| 304 | To Fight or to Flee? A Systematic Review of Ectopic Pregnancy Management and Complications During the Covid-19 Pandemic N/A | In Vivo | 2022 | | LitCov |
| 305 | Covid-19: Unusable PPE worth £4bn will be burned, says spending watchdog N/A | BMJ | 2022 | | LitCov |
| 306 | The effect of glutamine supplementation on serum levels of some inflammatory factors, oxidative stress and appetite in COVID-19 patients: a case-control study BACKGROUND: Malnutrition is seen in COVID-19 patients, and reducing malnutrition with appropriate therapies may improve these patients' health. This case–control study aimed to assess and compare serum levels of some inflammatory factors, oxidative stress, and appetite in COVID-19 patients with respiratory infections that receive glutamine treatment with a control group. METHODS: In this study, patients who consented to use glutamine were considered as the case group and other patients who did not use glutamine were considered as a control group. Two hundred twenty-two COVID-19 patients (51.2 ± 6.7) using l-Glutamine and 230 COVID-19 patients (51.3 ± 8.2) with similar age, gender, and clinical status, as the control group, were included in the study. For 5 days, the case group consumed 10 g of glutamine supplement three times per day. At the end of the 5 days, blood samples were taken again to test for serum levels of IL1β, tumor necrosis factor-α, malondialdehyde, and total antioxidant capacity, then all data were analyzed. RESULTS: Serum levels of β-1 interleukin, tumor necrosis factor-α and hs-CRP were significantly reduced with five days of glutamine supplementation (p < 0.05), and patients’ appetite during 5 days of glutamine supplementation compared with the control group had a significant increase (p < 0.05). CONCLUSION: Glutamine supplementation in COVID-19 patients with respiratory infection significantly reduces serum levels of interleukin-1 β, hs-CRP, and tumor necrosis factor-α and significantly increases appetite, so glutamine supplementation may be useful for COVID-19 patients in the hospital. | Inflammopharmacology | 2021 | | LitCov and CORD-19 |
| 307 | Titanium dioxide particles frequently present in face masks intended for general use require regulatory control Although titanium dioxide (TiO(2)) is a suspected human carcinogen when inhaled, fiber-grade TiO(2) (nano)particles were demonstrated in synthetic textile fibers of face masks intended for the general public. STEM-EDX analysis on sections of a variety of single use and reusable face masks visualized agglomerated near-spherical TiO(2) particles in non-woven fabrics, polyester, polyamide and bi-component fibers. Median sizes of constituent particles ranged from 89 to 184 nm, implying an important fraction of nano-sized particles (< 100 nm). The total TiO(2) mass determined by ICP-OES ranged from 791 to 152,345 µg per mask. The estimated TiO(2) mass at the fiber surface ranged from 17 to 4394 µg, and systematically exceeded the acceptable exposure level to TiO(2) by inhalation (3.6 µg), determined based on a scenario where face masks are worn intensively. No assumptions were made about the likelihood of the release of TiO(2) particles itself, since direct measurement of release and inhalation uptake when face masks are worn could not be assessed. The importance of wearing face masks against COVID-19 is unquestionable. Even so, these results urge for in depth research of (nano)technology applications in textiles to avoid possible future consequences caused by a poorly regulated use and to implement regulatory standards phasing out or limiting the amount of TiO(2) particles, following the safe-by-design principle. | Sci Rep | 2022 | | LitCov and CORD-19 |
| 308 | Covid-19: Government abandons mandatory vaccination of NHS staff N/A | BMJ | 2022 | | LitCov and CORD-19 |
| 309 | Impact of COVID-19 on patients awaiting ablation for atrial fibrillation N/A | Open Heart | 2022 | | LitCov |
| 310 | Clinical and Biochemical Characteristics of COVID-19 in a Primary Care Center in the South Batinah Region of Oman N/A | Cureus | 2022 | | LitCov |
| 311 | Citation impact and social media visibility of Great Barrington and John Snow signatories for COVID-19 strategy OBJECTIVE: The Great Barrington Declaration (GBD) and the John Snow Memorandum (JSM), each signed by numerous scientists, have proposed hotly debated strategies for handling the COVID-19 pandemic. The current analysis aimed to examine whether the prevailing narrative that GBD is a minority view among experts is true. METHODS: The citation impact and social media presence of the key GBD and JSM signatories was assessed. Citation data were obtained from Scopus using a previously validated composite citation indicator that incorporated also coauthorship and author order and ranking was against all authors in the same Science-Metrix scientific field with at least five full papers. Random samples of scientists from the longer lists of signatories were also assessed. The number of Twitter followers for all key signatories was also tracked. RESULTS: Among the 47 key GBD signatories, 20, 19 and 21, respectively, were top-cited authors for career impact, recent single-year (2019) impact or either. For comparison, among the 34 key JSM signatories, 11, 14 and 15, respectively, were top cited. Key signatories represented 30 different scientific fields (9 represented in both documents, 17 only in GBD and 4 only in JSM). In a random sample of n=30 scientists among the longer lists of signatories, five in GBD and three in JSM were top cited. By April 2021, only 19/47 key GBD signatories had personal Twitter accounts versus 34/34 of key JSM signatories; 3 key GBD signatories versus 10 key JSM signatories had >50 000 Twitter followers and extraordinary Kardashian K-indices (363–2569). By November 2021, four key GBD signatories versus 13 key JSM signatories had >50 000 Twitter followers. CONCLUSIONS: Both GBD and JSM include many stellar scientists, but JSM has far more powerful social media presence and this may have shaped the impression that it is the dominant narrative. | BMJ Open | 2022 | | LitCov and CORD-19 |
| 312 | Understanding the impact of the COVID-19 pandemic on psychiatric trainees and what can help N/A | BJPsych Bull | 2022 | | LitCov |
| 313 | Promoting Safety and Connection During COVID-19: Tiny Homes as an Innovative Response to Homelessness in the USA N/A | J Hum Rights Soc Work | 2022 | | LitCov |
| 314 | Pandemic preparedness: UK government kept coronavirus modelling secret N/A | BMJ | 2021 | | LitCov and CORD-19 |
| 315 | In Times of Adversity: A Neuroscience Perspective on Stress, Health and Implications for Society Post-pandemic The relationship between chronic stress and chronic disease (including mental illness) is well established: HPA-axis hyperactivity leads to hormonal dysregulation of primary mediators (eg, glucocorticoids, cytokines, etc.), allostatic overload, and neurological degradation, followed by clinical manifestations of disease. Amid the largest public health crisis of the century lay a myriad of challenges pushing people beyond their limit. From experiencing loss of connection or dealing with loss of life to financial shocks of COVID-19 lockdowns or infection by the SARS-CoV-2 virus, stress is at an all-time high, threatening both brain and mental health at scale. Fortunately, there is a way forward: the neuroscience of resilience teaches us that it is possible to resist, recover, and redirect the brain from trauma to re-establish balance in the body and improve well-being. At the same time, health follows a social gradient: adverse and protective psychosocial factors are shaped by wider social and economic determinants of health. This paper argues the neurobiology of stress is not separate from health disparities linked to adverse factors (ie, stress) created by complex social and economic contexts. Therefore, the field of neuroscience is challenged to inform multi-context and multi-level approaches and engage with decision-makers to enact policies and interventions aimed at promoting the resilient element in a wider population health context. Undoubtedly, achieving such a goal for current and future generations to benefit and lead healthier lives requires a heroic effort from all key stakeholders. The cost of willful neglect to resolve these issues is too expensive. | Yale J Biol Med | 2022 | | LitCov and CORD-19 |
| 316 | Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition N/A | Int J Obes (Lond) | 2022 | | LitCov and CORD-19 |
| 317 | Increased incidence of endophthalmitis after vitrectomy relative to face mask wearing during COVID-19 pandemic N/A | Br J Ophthalmol | 2022 | | LitCov |
| 318 | Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in eight provinces of South Africa in November 2021 In line with previous instalments of analysis from this ongoing study to monitor ‘Covid Seroprevalence’ among blood donors in South Africa, we report on analysis of 3395 samples obtained from 8 to 12 November 2021 in all provinces of South Africa except the Western Cape. As in our previous analyses, we see no evidence of age and sex dependence of prevalence, but substantial variation by province, and by race within each province, from which we generated provincial total point estimates (EC-74%; FS-75%; GP-68%; ZN-73%; LP-66; MP-73%; NC-63%; NW-81% ) and a ‘South Africa minus Western Cape’ national prevalence estimate of 71% (95%CI 69–74%). We note that sample collection occurred just before the omicron variant driven wave in South Africa, but otherwise present these results without significant interpretation. | Res Sq | 2022 | | CORD-19 |
| 319 | The effect of COVID-19 on prostate cancer testing in Australia N/A | BMC Urol | 2022 | | LitCov |
| 320 | Relating SARS-CoV-2 variants using cellular automata imaging N/A | Sci Rep | 2022 | | LitCov |
| 321 | Boosted immunity to the common cold might protect children from COVID-19 N/A | Nat Immunol | 2022 | | LitCov and CORD-19 |
| 322 | Risk factors for severe COVID-19 differ by age for hospitalized adults Risk stratification for hospitalized adults with COVID-19 is essential to inform decisions about individual patients and allocation of resources. So far, risk models for severe COVID outcomes have included age but have not been optimized to best serve the needs of either older or younger adults. Models also need to be updated to reflect improvements in COVID-19 treatments. This retrospective study analyzed data from 6906 hospitalized adults with COVID-19 from a community health system across five states in the western United States. Risk models were developed to predict mechanical ventilation illness or death across one to 56 days of hospitalization, using clinical data available within the first hour after either admission with COVID-19 or a first positive SARS-CoV-2 test. For the seven-day interval, models for age ≥ 18 and < 50 years reached AUROC 0.81 (95% CI 0.71–0.91) and models for age ≥ 50 years reached AUROC 0.82 (95% CI 0.77–0.86). Models revealed differences in the statistical significance and relative predictive value of risk factors between older and younger patients including age, BMI, vital signs, and laboratory results. In addition, for hospitalized patients, sex and chronic comorbidities had lower predictive value than vital signs and laboratory results. | Sci Rep | 2022 | | LitCov and CORD-19 |
| 323 | Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19 N/A | Nat Immunol | 2022 | | LitCov |
| 324 | Covid-19: Fact check-how many patients in hospital are unvaccinated? N/A | BMJ | 2022 | | LitCov |
| 325 | COVID-19 and Down syndrome: the spark in the fuel N/A | Nat Rev Immunol | 2022 | | LitCov |
| 326 | Variant to function mapping at single-cell resolution through network propagation N/A | Nat Biotechnol | 2022 | | LitCov |
| 327 | SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is accompanied by chronic neurological sequelae such as cognitive decline and mood disorder, but the underlying mechanisms have not yet been elucidated. We explored the possibility that the brain-infiltrating SARS-CoV-2 spike protein contributes to the development of neurological symptoms observed in COVID-19 patients in this study. Our behavioral study showed that administration of SARS-CoV-2 spike protein S1 subunit (S1 protein) to mouse hippocampus induced cognitive deficit and anxiety-like behavior in vivo. These neurological symptoms were accompanied by neuronal cell death in the dorsal and ventral hippocampus as well as glial cell activation. Interestingly, the S1 protein did not directly induce hippocampal cell death in vitro. Rather, it exerted neurotoxicity via glial cell activation, partially through interleukin-1β induction. In conclusion, our data suggest a novel pathogenic mechanism for the COVID-19-associated neurological symptoms that involves glia activation and non-cell autonomous hippocampal neuronal death by the brain-infiltrating S1 protein. | Sci Rep | 2022 | | LitCov and CORD-19 |
| 328 | How to interpret the total number of SARS-CoV-2 infections | Lancet | 2022 | | LitCov and CORD-19 |
| 329 | Demographic, Clinical and Co-Morbidity Characteristics of COVID-19 Patients: A Retrospective Cohort from a Tertiary Hospital in Kenya INTRODUCTION: The first documented case of COVID-19 in Kenya was recorded March of 2020. Co-morbidities including hypertension and diabetes have been associated with increased morbidity, hospitalization, and mortality among COVID-19 patients. This retrospective study describes the clinical characteristics, disease severity, and outcomes among the patient population at a tertiary hospital in Kenya. METHODS: This was a retrospective descriptive study of COVID-19 patients who were admitted between March 2020 and December 2020 at the Aga Khan University Hospital in Nairobi, Kenya. Data collected include patient demographic and baseline characteristics. Differences between patients who were known to have diabetes and hypertension during admission were compared for statistical significance. Difference between those who survived and those who died were also compared for statistical significance. RESULTS: A total of 913 records of patients were studied with a mean age of 51.2 years (SD = 16.7), 66.5% were male and 80.8% were of African origin. History of diabetes, hypertension, and HIV status were at 27.3%, 33.1%, and 2.3%, respectively. At presentation, 33.1% (302/913) of patients had known hypertension by history, and following admission, this proportion increased to 37.7% (344/913). At presentation, 27.3% (249/913) of patients had known diabetes. During hospital stay, 20.8% (190) more patients were found to have diabetes, raising the overall percent to 48.1% (439/913). When comparing diabetes and hypertension at baseline versus at the end of admission, diabetes increased by 20.8% (p < 0.001) and hypertension by 4.6% (p = 0.049). HIV co-infection was 2.3%, and no patient had tuberculosis. CONCLUSION: This study showed a high incidence of co-morbidities in patients infected with COVID-19. Diabetes was most common, followed by hypertension. All patients admitted with COVID-19 infection should routinely be tested for diabetes with HbA1c and have regular blood pressure monitoring in order to diagnose occult diabetes and hypertension. Adverse outcomes were found in patients with these co-morbidities and should be monitored and treated appropriately. | Int J Gen Med | 2022 | | LitCov and CORD-19 |
| 330 | Efficacy of COVID-19 treatments among geriatric patients: a systematic review N/A | Ther Adv Infect Dis | 2022 | | LitCov |
| 331 | Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission Transmission efficiency is a critical factor determining the size of an outbreak of infectious disease. Indeed, the propensity of SARS-CoV-2 to transmit among humans precipitated and continues to sustain the COVID-19 pandemic. Nevertheless, the number of new cases among contacts is highly variable and underlying reasons for wide-ranging transmission outcomes remain unclear. Here, we evaluated viral spread in golden Syrian hamsters to define the impact of temporal and environmental conditions on the efficiency of SARS-CoV-2 transmission through the air. Our data show that exposure periods as brief as one hour are sufficient to support robust transmission. However, the timing after infection is critical for transmission success, with the highest frequency of transmission to contacts occurring at times of peak viral load in the donor animals. Relative humidity and temperature had no detectable impact on transmission when exposures were carried out with optimal timing and high inoculation dose. However, contrary to expectation, trends observed with sub-optimal exposure timing and lower inoculation dose suggest improved transmission at high relative humidity or high temperature. In sum, among the conditions tested, our data reveal the timing of exposure to be the strongest determinant of SARS-CoV-2 transmission success and implicate viral load as an important driver of transmission. | PLoS Pathog | 2022 | | LitCov and CORD-19 |
| 332 | post-COVID-19 condition and its physical, mental and social implications: protocol of a 2-year longitudinal cohort study in the Belgian adult population N/A | Arch Public Health | 2022 | | LitCov |
| 333 | Envisioning sustainable and equitable World Health Assemblies N/A | BMJ Glob Health | 2022 | | LitCov |
| 334 | Sociodemographic and Policy Factors Associated with the Transmission of COVID-19: Analyzing Longitudinal Contact Tracing Data from a Northern Chinese City N/A | J Urban Health | 2022 | | LitCov |
| 335 | The COVID-19 pandemic-what have urologists learned? On 11 March 2020, the WHO declared the coronavirus disease 2019 (COVID-19) outbreak a pandemic and COVID-19 emerged as one of the biggest challenges in public health and economy in the twenty-first century. The respiratory tract has been the centre of attention, but COVID-19-associated complications affecting the genitourinary tract are reported frequently, raising concerns about possible long-term damage in these organs. The angiotensin-converting enzyme 2 (ACE2) receptor, which has a central role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invasion, is highly expressed in the genitourinary tract, indicating that these organs could be at a high risk of cell damage. The detection of SARS-CoV-2 in urine and semen is very rare; however, COVID-19 can manifest through urological symptoms and complications, including acute kidney injury (AKI), which is associated with poor survival, severe structural changes in testes and impairment of spermatogenesis, and hormonal imbalances (mostly secondary hypogonadism). The effect of altered total testosterone levels or androgen deprivation therapy on survival of patients with COVID-19 was intensively debated at the beginning of the pandemic; however, androgen inhibition did not show any effect in preventing or treating COVID-19 in a clinical study. Thus, urologists have a crucial role in detecting and managing damage of the genitourinary tract caused by COVID-19. | Nat Rev Urol | 2022 | | LitCov and CORD-19 |
| 336 | Rapid commentary: Ethical implications for clinical trialists and patients associated with COVID-19 research Pandemics disrupt clinical trials worldwide, with lasting effects on research. It can severely impact clinical trialists ability to conduct safe and ethically uncompromised trials. Hence, the mounting pressure results in ethically and morally distressing decisions faced by clinical trial professionals during pandemic situations. Whilst clinical trialists attempt to think about preparedness and responses during a pandemic, the need to have an ethical framework that has real-world applicability is imperative. Pandemics are a challenging time for all, however, the safety and access to support for clinical trialists and patients within clinical trials should be at the forefront for their organisations and the government. | World J Psychiatry | 2021 | | LitCov and CORD-19 |
| 337 | Pulmonary embolism during SARS-CoV-2 pandemic: clinical and radiological features Background. A high incidence of pulmonary embolism has been described during the coronavirus pandemic. Methods: This work is a single-center retrospective study which reviewed computed tomography pulmonary angiograms ordered due to suspected pulmonary embolism during two periods: from March 1, 2020 to May 31, 2020 (pandemic) and during the same interval in 2019 (control). Results: Twenty-two pulmonary embolism were diagnosed during the control period and 99 in the pandemic, 74 of which were associated with COVID-19. Of all patients hospitalized with COVID-19, 5.3% had a pulmonary embolism, with a delay between the two diagnoses of 9.1+/-8.4 days. During the pandemic, patients with pulmonary embolism had fewer predisposing conditions (previous pulmonary embolism 5.1% vs. 18.2%, p = .05; previous surgery 2% vs. 35.4%, p = .0001; deep vein thrombosis 11.1% vs. 45.5%, p=.0001); peripheral pulmonary embolisms were the most frequent (73.5% vs. 50%, p =. 029). Conclusions: There is an increased risk of having a pulmonary embolism during the SARS-CoV-2 pandemic, which affects patients with a different clinical profile and more often causes distal pulmonary embolisms. | Rev Clin Esp | 2022 | | LitCov and CORD-19 |
| 338 | Headlines play down the gravity of covid-19 in children N/A | BMJ | 2021 | | LitCov and CORD-19 |
| 339 | Higher frequency of new chest tumor diagnoses in emergency department due to the COVID-19 pandemic | Am J Emerg Med | 2022 | | LitCov and CORD-19 |
| 340 | Effects of the COVID-19 pandemic on provision of electroconvulsive therapy N/A | BJPsych Bull | 2022 | | LitCov and CORD-19 |
| 341 | Covid-19: Omicron variant is linked to steep rise in hospital admissions of very young children N/A | BMJ | 2022 | | LitCov |
| 342 | Scarce Resource Allocation in a Pandemic: A Protocol to Promote Equity, Timeliness and Transparency Shortages of equipment, medication, and staff under coronavirus disease 2019 may force hospitals to make wrenching decisions. Although bioethical guidance is available, published procedures for decision-making processes to resolve the time-sensitive conflicts are rare. Failure to establish decision-making procedures before scarcities arise exposes clinicians to moral distress and potential legal liability, entrenches existing systemic biases, and leaves hospitals without processes to guarantee transparency and consistency in the application of ethical guidelines. Formal institutional processes can reduce the panic, inequity, and irresolution that arise from confronting ethical conflicts under duress. Drawing on expertise in critical care medicine, bioethics, and political science, we propose a decision-making protocol to ensure fairness in the resolution of conflict, timely decision-making, and accountability to improve system response. | Crit Care Explor | 2021 | | LitCov and CORD-19 |
| 343 | Did border closures slow SARS-CoV-2? Despite the economic, social, and humanitarian costs of border closures, more than 1000 new international border closures were introduced in response to the 2020–2021 pandemic by nearly every country in the world. The objective of this study was to examine whether these border closures reduced the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Prior to 2020, the impacts of border closures on disease spread were largely unknown, and their use as a pandemic policy was advised against by international organizations. We tested whether they were helpful in reducing spread by using matching techniques on our hand-coded COVID Border Accountability Project (COBAP) Team database of international closures, converted to a time-series cross-sectional data format. We controlled for national-level internal movement restrictions (domestic lockdowns) using the Oxford COVID-19 Government Response Tracker (OxCGRT) time-series data. We found no evidence in favor of international border closures, whereas we found a strong association between national-level lockdowns and a reduced spread of SARS-CoV-2 cases. More research must be done to evaluate the byproduct effects of closures versus lockdowns as well as the efficacy of other preventative measures introduced at international borders. | Sci Rep | 2022 | | LitCov and CORD-19 |
| 344 | Understanding geopolitical determinants of health | Bull World Health Organ | 2021 | | CORD-19 |
| 345 | COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective COVID-19 vaccines have yielded definitive prevention and major reductions in morbidity and mortality from SARS-CoV-2 infection, even in the context of emerging and persistent variants-of-concern. Newer variants have revealed less vaccine protection against infection and attenuation of vaccine effects on transmission. COVID-19 vaccines still likely reduce transmission compared to not being vaccinated at all, even with variants of concern, however determining the magnitude of transmission reduction is constrained by challenges of performing these studies, requiring accurate linkage of infections to vaccine status and timing thereof, particularly within households. In this review we synthesize the currently available data on the impact of COVID-19 vaccines on infection, serious illness, and transmission; we also identify the challenges and opportunities associated with policy development based on this data. | Open Forum Infect Dis | 2022 | | LitCov and CORD-19 |
| 346 | Mental health after covid-19 N/A | BMJ | 2022 | | LitCov and CORD-19 |
| 347 | Distance education strategies to improve learning during the COVID-19 pandemic N/A | Nat Hum Behav | 2022 | | LitCov |
| 348 | Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis COVID-19 is characterized by hyperactivation by inflammatory cytokines and recruitment of macrophages, neutrophils, and other immune cells, all hallmarks of a strong inflammatory response that can lead to severe complications and multi-organ damage. Mortality in COVID-19 patients is associated with a high prevalence of neutrophil extracellular trap (NET) formation and microthrombosis that are exacerbated by hyperglycemia, diabetes, and old age. SARS-CoV-2 infection in humans and non-human primates have revealed long-term neurological consequences of COVID-19, possibly concomitant with the formation of Lewy bodies in the brain and invasion of the nervous system via the olfactory bulb. In this paper, we review the relevance of the human cathelicidin LL-37 in SARS-CoV-2 infections. LL-37 is an immunomodulatory, host defense peptide with direct anti-SARS-CoV-2 activity, and pleiotropic effects on the inflammatory response, neovascularization, Lewy body formation, and pancreatic islet cell function. The bioactive form of vitamin D and a number of other compounds induce LL-37 expression and one might predict its upregulation, could reduce the prevalence of severe COVID-19. We hypothesize upregulation of LL-37 will act therapeutically, facilitating efficient NET clearance by macrophages, speeding endothelial repair after inflammatory tissue damage, preventing α-synuclein aggregation, and supporting blood-glucose level stabilization by facilitating insulin release and islet β-cell neogenesis. In addition, it has been postulated that LL-37 can directly bind the S1 domain of SARS-CoV-2, mask angiotensin converting enzyme 2 (ACE2) receptors, and limit SARS-CoV-2 infection. Purposeful upregulation of LL-37 could also serve as a preventative and therapeutic strategy for SARS-CoV-2 infections. | Front Immunol | 2022 | | LitCov and CORD-19 |
| 349 | Comparison of pulmonary function test, diffusion capacity, blood gas analysis and CT scan in patients with and without persistent respiratory symptoms following COVID-19 BACKGROUND: Long-lasting symptoms following SARS-CoV2-infection have been described in several studies. However, there is only limited knowledge about the ongoing pathophysiology and the association with pathological findings in medical examinations. METHODS: In this post hoc analysis of a prospective trial, 135 patients following COVID-19 were enrolled and grouped with respect to the presence or absence of respiratory ongoing symptoms following COVID-19. Pulmonary function test (PFT), diffusion capacity measurement (TLCO SB and TLCO/VA), blood gas analysis (BGA), laboratory tests and high-resolution computed tomography (HRCT) of patients with persistent respiratory symptoms were compared to those of asymptomatic patients. RESULTS: In this analysis, 71% (96/135) of all patients (mean age 49 years; range 20–91 years) reported long-lasting symptoms after a median (IQR) of 85 days (60–116) following COVID-19 whereby 57.8% (78/135) complained about persistent pulmonary symptoms. Pathological findings in blood test, PFT, TLCO, BGA and/or HRCT were found in 71.8% and 64.1% of patients with and without long-lasting respiratory symptoms respectively. Patients with persistent respiratory symptoms were significantly younger and presented a significant lower FVC (%), TLC (L), and TLCO SB compared to asymptomatic patients (p < 0.05). The multiple logistic regression results in a significant effect of age (p = 0.004) and TLCO SB (p = 0.042). CONCLUSION: Following COVID-19, a large proportion of patients experience ongoing symptoms, whereby the respiratory symptoms are the predominant complaints. Compared to asymptomatic patients, patients with ongoing symptoms were younger and presented a significant lower FVC, TLC and TLCO SB. The multiple logistic regression demonstrated only a significant association between the TLCO SB as the only PFT parameter and the perceived symptoms. | BMC Pulm Med | 2022 | | LitCov and CORD-19 |
| 350 | Embolization of a Renal Solid Bleeding Lesion in Intensive Care Unit in a Critically Ill Patient with Severe Acute Respiratory Syndrome-Related Coronavirus Infection and Difficult Mobilization due to ECMO and Continuous Renal Replacement Therapy | Cardiovasc Intervent Radiol | 2022 | | LitCov and CORD-19 |
